Value of cell-bound complement activation products in the diagnosis of systemic lupus erythematosus
10.13602/j.cnki.jcls.2019.01.08
- VernacularTitle:细胞结合补体活化产物在系统性红斑狼疮诊断中的价值
- Author:
Jianjun HUANG
1
;
Guangxi LI
2
;
Jun ZHANG
2
;
Zhi LI
3
;
Long CHENG
1
;
Peng ZHANG
1
;
Xiaoning LI
1
;
Gang FENG
1
Author Information
1. Department of Laboratory Medicine, Yijishan Hospital of Wannan Medical College
2. Department of Hematopathology,Yijishan Hospital of Wannan Medical College
3. Department of Rheumatology,Yijishan Hospital of Wannan Medical College
- Publication Type:Journal Article
- Keywords:
complement activation product;
systemic lupus erythematosus;
C3d;
C4d
- From:
Chinese Journal of Clinical Laboratory Science
2019;37(1):33-37
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the values of T lymphocyte-bound complement activation products such as T-C3d and T-C4d, B lymphocyte-bound complement activation products such as B-C3d and B-C4d and erythrocyte-bound complement activation products such as E-C3d and E-C4d in the diagnosis of systemic lupus erythematosus (SLE).
Methods:Peripheral blood samples from 68 SLE patients, 70 patients with non-SLE autoimmune diseases and 68 healthy controls were collected randomly, and the expression levels of T-C4d, B-C4d, E-C4d, T-C3d, B-C3d and E-C3d in these samples were detected by flow cytometry. Meanwhile, antinuclear antibodies (ANA), anti-double stranded DNA antibodies (anti-dsDNA), peripheral blood cell count and other markers were also detected. The differences of cell-bound complement activation products in three groups were analyzed with the area under the receiver operating characteristic curve (AUC), nonparametric test, sensitivity and specificity.
Results:The specific median fluorescence intensity (SMFI) of T-C4d, B-C4d, E-C4d, T-C3d, B-C3d and E-C3d in SLE patients were significantly higher than those in the patients with non-SLE autoimmune diseases and healthy controls (all P＜0.05). The SMFI (median \[P 25, P 75\]) of T-C4d, B-C4d and E-C4d in SLE patients were 3.8(1.2, 13.1), 22.1(6.2, 67.9) and 19.6(1.8, 52.4), respectively. The SMFI of T-C4d, B-C4d and E-C4d in SLE patients with reduced red blood cells and/or lymphocytes were significantly higher than that with normal red blood cell and lymphocyte count (all P＜0.05). The AUCs of T-C4d, B-C4d, E-C4d, T-C3d, B-C3d and E-C3d were 0.711, 0.763, 0.663, 0.631, 0.611 and 0.615, respectively (all P＜0.05). The sensitivity of the combination of T-C4d with B-C4d (73.5%) in the diagnosis of SLE was superior to that of anti-dsDNA (36.8%).
Conclusion:The cell-bound complement activation products (CB-CAPs) are specifically expressed in SLE patients, and their combination detection is helpful for the diagnosis of SLE.
- Full text:20180620-黄建军-终审稿.docx
